Skip to main content
. 2019 Jul 4;182(1):180–189. doi: 10.1111/bjd.17918

Figure 4.

Figure 4

Effect of antidrug antibodies (ADAs) on percentage Psoriasis Area and Severity Index (PASI) improvement through week 12 or week 52. (a) Percentage PASI improvement through week 12 for patients treated with 100 mg in part 1. (b) Percentage PASI improvement through weeks 52–64 for patients treated with 100 mg continuously in parts 1, 2 and 3. (c) Percentage PASI improvement through week 12 for patients treated with 200 mg in part 1. (d) Percentage PASI improvement through weeks 52–64 for patients treated with 200 mg continuously in parts 1, 2 and 3. Continuous treatment with tildrakizumab means that patients treated with placebo or etanercept and then tildrakizumab were not included in the analysis. NAb, neutralizing antibodies.